(Total Views: 84)
Posted On: 09/04/2024 8:55:09 AM
Post# of 25385
$CBDW 1606 Corp. Signs Letter of Intent to Acquire a Strategic Stake in Adnexus, a Leading AI Biotech Company
https://www.accesswire.com/911938/1606-corp-s...ch-company
SEATTLE, WA / ACCESSWIRE / September 4, 2024 / 1606 Corp. (OTC Pink:CBDW), a leader in AI technology development, is pleased to announce that it has signed a nonbinding Letter of Intent (LOI) to acquire a strategic stake in Adnexus, a pioneering company at the forefront of Artificial Intelligence innovations in early drug discovery and infectious disease research.
This potential strategic investment underscores 1606 Corp.'s commitment to expanding its technological footprint and enhancing its capabilities in the rapidly evolving field of AI. We believe the integration of Adnexus's cutting-edge AI research and development expertise would significantly bolster 1606 Corp.'s portfolio, bringing advanced solutions to the intersection of artificial intelligence and healthcare and biotech.
Adnexus has been recognized for its groundbreaking work in leveraging AI to drive early drug discovery and develop critical treatments for infectious diseases including HIV and SARS-COV-2. By aligning with Adnexus, 1606 Corp. aims to accelerate innovation and development within the healthcare sector, combining its strengths in conversational AI and chatbot technology with Adnexus's pioneering research efforts. For a deeper dive into Adnexus' groundbreaking technology, visit their website at www.adnexusbiotech.com.
Adnexus has distinguished itself in the field of biotechnology through its innovative approach to developing therapeutic solutions. Their proprietary methodology is centered around utilizing human "immune-B cells" sourced from individuals who have naturally recovered from target viruses. This unique process enables the creation of fully human monoclonal antibodies that exhibit natural affinity and specificity.
Austen Lambrecht, CEO of 1606 Corp., stated, "We are thrilled to enter into this agreement with Adnexus. Their exceptional work in AI-driven drug discovery and infectious disease treatment aligns perfectly with our vision of harnessing advanced AI technologies to create impactful solutions. This partnership represents a significant step forward in our strategy to diversify and enhance our technological capabilities."
The transaction is expected to be finalized following customary due diligence and the fulfillment of certain conditions as stated in the LOI. Both companies anticipate that this strategic alignment will generate significant value for shareholders, advance technological development, and drive innovation in their respective fields.
CEO, Austen Lambrecht and 1606 Corp. (CBDW) are glad to announce that we will be presenting at the 150th NIBA Show in Fort Lauderdale on Thursday, August 5th.
https://www.accesswire.com/911938/1606-corp-s...ch-company
SEATTLE, WA / ACCESSWIRE / September 4, 2024 / 1606 Corp. (OTC Pink:CBDW), a leader in AI technology development, is pleased to announce that it has signed a nonbinding Letter of Intent (LOI) to acquire a strategic stake in Adnexus, a pioneering company at the forefront of Artificial Intelligence innovations in early drug discovery and infectious disease research.
This potential strategic investment underscores 1606 Corp.'s commitment to expanding its technological footprint and enhancing its capabilities in the rapidly evolving field of AI. We believe the integration of Adnexus's cutting-edge AI research and development expertise would significantly bolster 1606 Corp.'s portfolio, bringing advanced solutions to the intersection of artificial intelligence and healthcare and biotech.
Adnexus has been recognized for its groundbreaking work in leveraging AI to drive early drug discovery and develop critical treatments for infectious diseases including HIV and SARS-COV-2. By aligning with Adnexus, 1606 Corp. aims to accelerate innovation and development within the healthcare sector, combining its strengths in conversational AI and chatbot technology with Adnexus's pioneering research efforts. For a deeper dive into Adnexus' groundbreaking technology, visit their website at www.adnexusbiotech.com.
Adnexus has distinguished itself in the field of biotechnology through its innovative approach to developing therapeutic solutions. Their proprietary methodology is centered around utilizing human "immune-B cells" sourced from individuals who have naturally recovered from target viruses. This unique process enables the creation of fully human monoclonal antibodies that exhibit natural affinity and specificity.
Austen Lambrecht, CEO of 1606 Corp., stated, "We are thrilled to enter into this agreement with Adnexus. Their exceptional work in AI-driven drug discovery and infectious disease treatment aligns perfectly with our vision of harnessing advanced AI technologies to create impactful solutions. This partnership represents a significant step forward in our strategy to diversify and enhance our technological capabilities."
The transaction is expected to be finalized following customary due diligence and the fulfillment of certain conditions as stated in the LOI. Both companies anticipate that this strategic alignment will generate significant value for shareholders, advance technological development, and drive innovation in their respective fields.
CEO, Austen Lambrecht and 1606 Corp. (CBDW) are glad to announce that we will be presenting at the 150th NIBA Show in Fort Lauderdale on Thursday, August 5th.
(0)
(0)Scroll down for more posts ▼
